SIRONA BIOCHEM CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.065 CAD | -7.14% |
|
+8.33% | -45.83% |
| 04-08 | Sirona Biochem Provides Update on Anti-Aging Product | MT |
| 04-04 | Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding | CI |
| Sales 2022 | 672K 491K 39.35M | Sales 2023 | 34.78K 25.42K 2.04M | Capitalization | 21.44M 15.67M 1.26B |
|---|---|---|---|---|---|
| Net income 2022 | -3M -2.19M -176M | Net income 2023 | -2M -1.46M -117M | EV / Sales 2022 | 48.8 x |
| Net Debt 2022 | 48.04K 35.12K 2.81M | Net Debt 2023 | 1.61M 1.18M 94.34M | EV / Sales 2023 | 663 x |
| P/E ratio 2022 |
-8.81
x | P/E ratio 2023 |
-8.43
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.89% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -7.14% | ||
| 1 week | +8.33% | ||
| 3 months | -35.00% | ||
| 6 months | -23.53% | ||
| Current year | -45.83% |
1 week
0.06
0.07
1 month
0.060.07
Current year
0.060.12
1 year
0.060.18
3 years
0.060.38
5 years
0.060.69
10 years
0.060.69
| Managers | Title | Age | Since |
|---|---|---|---|
Howard Verrico
CEO | Chief Executive Officer | - | 18/10/06 |
| Director of Finance/CFO | - | 28/04/09 | |
| Chief Tech/Sci/R&D Officer | - | 30/03/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Howard Verrico
CEO | Chief Executive Officer | - | 18/10/06 |
Alex Marazzi
BRD | Director/Board Member | - | 18/10/06 |
| Director of Finance/CFO | - | 28/04/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.065 | -7.14% | 56,001 |
| 25/04/24 | 0.07 | +16.67% | 25,009 |
| 24/04/24 | 0.06 | -7.69% | 10,000 |
| 22/04/24 | 0.065 | +8.33% | 57,416 |
Delayed Quote Toronto S.E., April 26, 2024 at 06:09 pm
More quotes
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChemâs proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).
Calendar
25/06/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -45.83% | 12.18M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SBM Stock
